GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (LTS:0RAG) » Definitions » Debt-to-EBITDA

Abionyx Pharma (LTS:0RAG) Debt-to-EBITDA : -1.43 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Abionyx Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.82 Mil. Abionyx Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €2.58 Mil. Abionyx Pharma's annualized EBITDA for the quarter that ended in Dec. 2023 was €-2.37 Mil. Abionyx Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.43.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Abionyx Pharma's Debt-to-EBITDA or its related term are showing as below:

LTS:0RAG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.31   Med: -0.87   Max: 0.53
Current: -1.01

During the past 11 years, the highest Debt-to-EBITDA Ratio of Abionyx Pharma was 0.53. The lowest was -1.31. And the median was -0.87.

LTS:0RAG's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.31 vs LTS:0RAG: -1.01

Abionyx Pharma Debt-to-EBITDA Historical Data

The historical data trend for Abionyx Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma Debt-to-EBITDA Chart

Abionyx Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 -0.01 -0.87 -1.00 -1.01

Abionyx Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.78 -0.93 -1.36 -0.99 -1.43

Competitive Comparison of Abionyx Pharma's Debt-to-EBITDA

For the Biotechnology subindustry, Abionyx Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abionyx Pharma's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's Debt-to-EBITDA falls into.



Abionyx Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Abionyx Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.815 + 2.575) / -3.346
=-1.01

Abionyx Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.815 + 2.575) / -2.368
=-1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Abionyx Pharma  (LTS:0RAG) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Abionyx Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Abionyx Pharma (LTS:0RAG) Business Description

Traded in Other Exchanges
Address
33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (LTS:0RAG) Headlines

No Headlines